{"id":37570,"date":"2023-06-26T16:36:39","date_gmt":"2023-06-26T14:36:39","guid":{"rendered":"https:\/\/www.satt.fr\/?p=37570"},"modified":"2023-06-26T16:36:39","modified_gmt":"2023-06-26T14:36:39","slug":"everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/","title":{"rendered":"EVerZom et Summit Pharmaceuticals concluent un accord de distribution exclusif au Japon"},"content":{"rendered":"

Le 2 juin 2023, Summit Pharmaceuticals International, une entreprise biopharmaceutique, et la start-up EVerZom ont conclu un accord de distribution exclusive au Japon.<\/p>\n

EVerZom, rappelons-le, est une start-up sp\u00e9cialis\u00e9e dans le domaine de la biopharmaceutique. Elle d\u00e9veloppe un proc\u00e9d\u00e9 adaptable \u00e0 grande \u00e9chelle qui stimule la lib\u00e9ration des v\u00e9sicules extracellulaires, lesquelles poss\u00e8dent la capacit\u00e9 de r\u00e9g\u00e9n\u00e9rer les tissus endommag\u00e9s. Cette innovation ouvre de nouvelles perspectives dans le domaine de la r\u00e9g\u00e9n\u00e9ration tissulaire.<\/p>\n

Quant \u00e0 Summit Pharmaceuticals, il s’agit d’une entreprise biopharmaceutique japonaise sp\u00e9cialis\u00e9e dans la bioproduction de v\u00e9sicules extracellulaires. La position de Summit Pharmaceuticals en tant qu’acteur et expert majeur sur le march\u00e9 japonais garantit \u00e0 EVerZom un suivi de haute qualit\u00e9 et un soutien en recherche et d\u00e9veloppement dans diff\u00e9rents domaines.<\/p>\n

SPI s\u2019engage \u00e0 travailler avec EVerZom pour continuer \u00e0 promouvoir et \u00e0 d\u00e9velopper la recherche sur les exosomes sur le march\u00e9 japonais.<\/p>\n

Lire le communiqu\u00e9 de presse<\/a><\/p>\n

En savoir plus sur EVerZom<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Le 2 juin 2023, Summit Pharmaceuticals International, une entreprise biopharmaceutique, et la start-up EVerZom ont conclu un accord de distribution exclusive au Japon. EVerZom, rappelons-le, est une start-up sp\u00e9cialis\u00e9e dans le domaine de la biopharmaceutique. Elle d\u00e9veloppe un proc\u00e9d\u00e9 adaptable \u00e0 grande \u00e9chelle qui stimule la lib\u00e9ration des v\u00e9sicules extracellulaires, lesquelles poss\u00e8dent la capacit\u00e9 de […]<\/p>\n","protected":false},"author":51,"featured_media":37571,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[536],"tags":[],"class_list":["post-37570","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite"],"acf":[],"yoast_head":"\nEVerZom et Summit Pharmaceuticals concluent un accord de distribution exclusif au Japon - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"marianne.lebolloch@erganeo.com\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/\"},\"author\":{\"name\":\"marianne.lebolloch@erganeo.com\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/1c35c421c97b27b2f92f38464c7a84ba\"},\"headline\":\"EVerZom et Summit Pharmaceuticals concluent un accord de distribution exclusif au Japon\",\"datePublished\":\"2023-06-26T14:36:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/\"},\"wordCount\":182,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/06\/Article-EVerZom.png\",\"articleSection\":[\"Actualit\u00e9\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/\",\"url\":\"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/\",\"name\":\"EVerZom et Summit Pharmaceuticals concluent un accord de distribution exclusif au Japon - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/06\/Article-EVerZom.png\",\"datePublished\":\"2023-06-26T14:36:39+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/1c35c421c97b27b2f92f38464c7a84ba\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/06\/Article-EVerZom.png\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/06\/Article-EVerZom.png\",\"width\":1200,\"height\":960},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EVerZom et Summit Pharmaceuticals concluent un accord de distribution exclusif au Japon\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d'Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/1c35c421c97b27b2f92f38464c7a84ba\",\"name\":\"marianne.lebolloch@erganeo.com\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/marianne-lebollocherganeo-com\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EVerZom et Summit Pharmaceuticals concluent un accord de distribution exclusif au Japon - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/","twitter_misc":{"Written by":"marianne.lebolloch@erganeo.com","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/"},"author":{"name":"marianne.lebolloch@erganeo.com","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/1c35c421c97b27b2f92f38464c7a84ba"},"headline":"EVerZom et Summit Pharmaceuticals concluent un accord de distribution exclusif au Japon","datePublished":"2023-06-26T14:36:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/"},"wordCount":182,"image":{"@id":"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/06\/Article-EVerZom.png","articleSection":["Actualit\u00e9"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/","url":"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/","name":"EVerZom et Summit Pharmaceuticals concluent un accord de distribution exclusif au Japon - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/06\/Article-EVerZom.png","datePublished":"2023-06-26T14:36:39+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/1c35c421c97b27b2f92f38464c7a84ba"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/06\/Article-EVerZom.png","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/06\/Article-EVerZom.png","width":1200,"height":960},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/everzom-et-summit-pharmaceuticals-concluent-un-accord-de-distribution-exclusif-au-japon\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"EVerZom et Summit Pharmaceuticals concluent un accord de distribution exclusif au Japon"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d'Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/1c35c421c97b27b2f92f38464c7a84ba","name":"marianne.lebolloch@erganeo.com","url":"https:\/\/www.satt.fr\/en\/author\/marianne-lebollocherganeo-com\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/37570","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/51"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=37570"}],"version-history":[{"count":1,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/37570\/revisions"}],"predecessor-version":[{"id":37573,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/37570\/revisions\/37573"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/37571"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=37570"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=37570"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=37570"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}